

Ulrich Specks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5534550/publications.pdf>

Version: 2024-02-01

245
papers

18,928
citations

12303

69
h-index

12910

131
g-index

252
all docs

252
docs citations

252
times ranked

9990
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
2	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	13.9	682
3	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	13.9	611
4	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
5	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 71.	18.1	443
6	Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 262-268.	6.7	423
7	Antineutrophil cytoplasmic antibodies. <i>Arthritis and Rheumatism</i> , 1998, 41, 1521-1537.	6.7	404
8	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. <i>Arthritis and Rheumatism</i> , 2001, 44, 912-920.	6.7	400
9	Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis. <i>Chest</i> , 2003, 124, 177-185.	0.4	383
10	Rituximab for Refractory Wegener's Granulomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 180-187.	2.5	379
11	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
12	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. <i>Arthritis and Rheumatism</i> , 2001, 44, 2836-2840.	6.7	362
13	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	3.5	302
14	Churg-Strauss syndrome. <i>American Journal of Medicine</i> , 2003, 115, 284-290.	0.6	282
15	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , 2005, 142, 620.	2.0	277
16	Anticytoplasmic Autoantibodies in the Diagnosis and Follow-Up of Wegener's Granulomatosis. <i>Mayo Clinic Proceedings</i> , 1989, 64, 28-36.	1.4	272
17	Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center. <i>Arthritis and Rheumatism</i> , 2012, 64, 3770-3778.	6.7	248
18	Rituximab Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2188-2198.	2.2	247

#	ARTICLE	IF	CITATIONS
19	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. <i>Annals of Internal Medicine</i> , 2007, 147, 611.	2.0	234
20	ANCA Are Detectable in Nearly All Patients with Active Severe Wegener's Granulomatosis. <i>American Journal of Medicine</i> , 2007, 120, 643.e9-643.e14.	0.6	228
21	ANCA-associated vasculitis – clinical utility of using ANCA specificity to classify patients. <i>Nature Reviews Rheumatology</i> , 2016, 12, 570-579.	3.5	219
22	Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	217
23	Integrin and Arg-Gly-Asp Dependence of Cell Adhesion to the Native and Unfolded Triple Helix of Collagen Type VI. <i>Experimental Cell Research</i> , 1993, 206, 167-176.	1.2	204
24	Cutaneous Wegener's granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, 605-612.	0.6	203
25	Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2954-2965.	6.7	203
26	Exostosin 1/Exostosin 2 – Associated Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1123-1136.	3.0	198
27	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.5	196
28	Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 1608-1618.	6.7	195
29	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Arthritis and Rheumatism</i> , 2005, 52, 2168-2178.	6.7	171
30	Pneumocystis Pneumonia in Patients Treated With Rituximab. <i>Chest</i> , 2013, 144, 258-265.	0.4	154
31	Diffuse alveolar hemorrhage syndromes. <i>Current Opinion in Rheumatology</i> , 2001, 13, 12-17.	2.0	147
32	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
33	Cocaine-Induced Midline Destructive Lesions. <i>Medicine (United States)</i> , 2001, 80, 391-404.	0.4	138
34	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA-DPB1*04</i> and <i>SEMA6A</i> Gene Variants: Evidence From Genome-Wide Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2457-2468.	6.7	138
35	BAFF is elevated in serum of patients with Wegener's granulomatosis. <i>Journal of Autoimmunity</i> , 2005, 25, 298-302.	3.0	137
36	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	3.0	137

#	ARTICLE	IF	CITATIONS
37	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	2.9	132
38	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	2.9	130
39	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1376-1379.	0.5	128
40	Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 905-919.	2.2	126
41	The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota. <i>Arthritis and Rheumatology</i> , 2017, 69, 2338-2350.	2.9	126
42	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
43	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.5	109
44	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	1.6	109
45	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 704-704.	0.5	106
46	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2016, 68, 1467-1476.	2.9	94
47	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93
48	Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2865-2871.	0.4	92
49	Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvement—A Prospective, Open-Label Pilot Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 445-453.	2.2	89
50	Pulmonary Involvement in Henoch-Schlein Purpura. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1151-1157.	1.4	87
51	Alpha ₁ -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3760-3767.	6.7	87
52	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	1.0	87
53	Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. <i>Journal of Rheumatology</i> , 2002, 29, 309-16.	1.0	87
54	Airway Involvement in Wegener's Granulomatosis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 755-775.	0.8	83

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	2.9	82
56	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
57	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
58	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
59	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. <i>Journal of Rheumatology</i> , 2008, 35, 2017-23.	1.0	78
60	Detection of Anti-Neutrophil Cytoplasmic Antibodies under Actual Clinical Testing Conditions. <i>Clinical Immunology</i> , 2002, 103, 196-203.	1.4	77
61	Pathogenesis of ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 481-493.	2.1	77
62	Sinonasal Osteocartilaginous Necrosis in Cocaine Abusers: Experience in 25 Patients. <i>American Journal of Rhinology & Allergy</i> , 2003, 17, 33-43.	2.3	76
63	Echocardiographic Findings in Patients With Wegener Granulomatosis. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1435-1440.	1.4	75
64	Update on Diffuse Alveolar Hemorrhage and Pulmonary Vasculitis. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 587-600.	0.7	75
65	Myeloperoxidase-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	2.9	75
66	Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunocomplexes. <i>Journal of Immunological Methods</i> , 1998, 211, 111-123.	0.6	74
67	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20736-20741.	3.3	74
68	Bronchoalveolar Lavage Fluid Angiotensin-converting Enzyme in Interstitial Lung Diseases. <i>The American Review of Respiratory Disease</i> , 1990, 141, 117-123.	2.9	73
69	Melanoma Antigen A4 Is Expressed in Non-Small Cell Lung Cancers and Promotes Apoptosis. <i>Cancer Research</i> , 2006, 66, 4693-4700.	0.4	73
70	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. <i>Transplantation</i> , 2011, 91, 1370-1375.	0.5	71
71	Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 597-606.	1.4	69
72	Pituitary Dysfunction in Granulomatosis With Polyangiitis: The Mayo Clinic Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3988-3994.	1.8	68

#	ARTICLE	IF	CITATIONS
73	Expression of Type VI Collagen mRNA During Wound Healing. <i>Journal of Investigative Dermatology</i> , 1993, 100, 329-334.	0.3	65
74	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 112.	0.7	65
75	Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis and Rheumatism</i> , 2001, 44, 463-468.	6.7	62
76	Outcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU. <i>Chest</i> , 2007, 131, 972-976.	0.4	62
77	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2011, 63, 1777-1781.	1.5	60
78	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). <i>Autoimmunity Reviews</i> , 2013, 12, 501-505.	2.5	60
79	Immunohistochemical localization of collagen VI in diabetic glomeruli. <i>Kidney International</i> , 1994, 45, 1648-1656.	2.6	59
80	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
81	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i139-i145.	0.4	59
82	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , 2011, 63, 2495-2503.	6.7	58
83	Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. <i>FEBS Letters</i> , 2005, 579, 5305-5312.	1.3	53
84	Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. <i>Arthritis and Rheumatism</i> , 2008, 58, 1546-1551.	6.7	53
85	Pulmonary Necrotizing Granulomas of Unknown Cause. <i>Chest</i> , 2013, 144, 813-824.	0.4	53
86	Anti-Neutrophil Cytoplasmic Antibodies. <i>Mayo Clinic Proceedings</i> , 1994, 69, 1197-1198.	1.4	52
87	Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis. <i>American Journal of Kidney Diseases</i> , 2009, 54, 542-545.	2.1	52
88	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 251-257.	2.2	50
89	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	1.5	49
90	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1114-1121.	2.9	49

#	ARTICLE	IF	CITATIONS
91	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2688-2704.	3.0	48
92	Primary Antiphospholipid Syndrome-Associated Diffuse Alveolar Hemorrhage. <i>Arthritis Care and Research</i> , 2014, 66, 301-310.	1.5	47
93	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1033-1044.	3.0	47
94	Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha3(VI) chain. <i>FEBS Journal</i> , 1994, 225, 573-580.	0.2	46
95	Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. <i>FEBS Letters</i> , 1996, 390, 265-270.	1.3	46
96	Long-Term Follow-up of Repair of External Nasal Deformities in Patients With Wegener's Granulomatosis. <i>Laryngoscope</i> , 2002, 112, 731-737.	1.1	46
97	Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1069-1071.	2.5	46
98	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1508-1517.	0.4	46
99	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis. <i>Journal of Rheumatology</i> , 2011, 38, 1048-1054.	1.0	45
100	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Associated Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	2.9	45
101	Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. <i>Clinical Immunology</i> , 2003, 109, 330-337.	1.4	43
102	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 902-910.	6.7	43
103	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. <i>Current Opinion in Rheumatology</i> , 2012, 24, 15-23.	2.0	43
104	Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. <i>FEBS Letters</i> , 1997, 408, 187-190.	1.3	41
105	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	1.0	40
106	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.4	40
107	Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. <i>Journal of Autoimmunity</i> , 2017, 84, 122-131.	3.0	40
108	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	1.0	39

#	ARTICLE	IF	CITATIONS
109	Role of Testing for Anticytoplasmic Autoantibodies in the Differential Diagnosis of Scleritis and Orbital Pseudotumor. <i>Mayo Clinic Proceedings</i> , 1990, 65, 1110-1117.	1.4	37
110	Cell adhesion to type-VI collagen. <i>Biochemical Society Transactions</i> , 1991, 19, 843-847.	1.6	36
111	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	2.5	36
112	Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. <i>Journal of Autoimmunity</i> , 2010, 35, 299-308.	3.0	35
113	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	1.1	35
114	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. <i>Journal of Rheumatology</i> , 2007, 34, 2446-50.	1.0	35
115	Pulmonary Henoch-Schönlein Purpura. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1151-1157.	1.4	34
116	Meningeal Involvement in Wegener Granulomatosis. <i>Mayo Clinic Proceedings</i> , 2000, 75, 856-859.	1.4	33
117	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
118	Lung involvement in ANCA-associated vasculitis. <i>Presse Medicale</i> , 2020, 49, 104039.	0.8	33
119	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007, 34, 1357-71.	1.0	33
120	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. <i>Rheumatology</i> , 2019, 58, 1707-1709.	0.9	32
121	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. <i>Journal of Renal Injury Prevention</i> , 2017, 6, 18-25.	0.6	32
122	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2488-95.	1.0	32
123	Mapping of Conformational Epitopes on Human Proteinase 3, the Autoantigen of Wegener's Granulomatosis. <i>Journal of Immunology</i> , 2010, 185, 387-399.	0.4	31
124	Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease. <i>Pharmacological Reviews</i> , 2016, 68, 603-630.	7.1	30
125	Does infection play a role in the pathogenesis of pulmonary vasculitis?. <i>Seminars in Respiratory Infections</i> , 2003, 18, 17-22.	1.3	29
126	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2014, 66, 428-432.	2.9	28

#	ARTICLE	IF	CITATIONS
127	What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. <i>Arthritis Research</i> , 2000, 2, 263.	2.0	27
128	Eosinophilic Granulomatosis With Polyangiitis. <i>Chest</i> , 2020, 157, 1086-1099.	0.4	26
129	ARE ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES PATHOGENIC?. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 815-832.	0.8	25
130	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	2.9	25
131	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	2.9	25
132	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1710-1721.	0.4	25
133	Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. <i>Journal of Immunological Methods</i> , 2000, 244, 117-131.	0.6	24
134	Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. <i>Kidney International</i> , 2003, 63, 756-760.	2.6	24
135	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	3.2	24
136	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	3.0	24
137	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	2.1	24
138	A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. <i>Journal of Immunological Methods</i> , 2005, 307, 62-72.	0.6	23
139	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
140	Methotrexate for Wegener's granulomatosis: What is the evidence?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2237-2242.	6.7	22
141	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. <i>Journal of Rheumatology</i> , 2007, 34, 1027-31.	1.0	22
142	Clinical utility of ANCA tests for the dermatologist. <i>International Journal of Dermatology</i> , 2003, 42, 859-869.	0.5	21
143	Pulmonary Capillaritis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 547-555.	0.8	21
144	A Monoclonal Antibody (MCPR3-7) Interfering with the Activity of Proteinase 3 by an Allosteric Mechanism. <i>Journal of Biological Chemistry</i> , 2013, 288, 26635-26648.	1.6	21

#	ARTICLE	IF	CITATIONS
145	Accurate Relapse Prediction in ANCA-Associated Vasculitisâ€”the Search for the Holy Grail. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 505-507.	3.0	21
146	The Pharmacogenomic Association of FcÎ³ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€”Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	2.9	21
147	Clinical Manifestations and Longâ€”Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
148	Lesions of the Respiratory Tract Associated With the Finding of Anti-Neutrophil Cytoplasmic Autoantibodies With a Perinuclear Staining Pattern. <i>Mayo Clinic Proceedings</i> , 1994, 69, 819-824.	1.4	20
149	Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. <i>Respirology</i> , 2016, 21, 734-738.	1.3	20
150	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018, 57, 639-650.	0.9	20
151	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	1.0	20
152	Are animal models of vasculitis suitable tools?. <i>Current Opinion in Rheumatology</i> , 2000, 12, 11-19.	2.0	19
153	Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. <i>Clinics in Chest Medicine</i> , 2019, 40, 573-582.	0.8	19
154	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	2.2	19
155	Wegener's granulomatosis presenting as multiple bilateral renal masses. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 984-987.	0.4	18
156	Coexistent Pulmonary Granulomatosis With Polyangiitis (Wegener Granulomatosis) and Crohn Disease. <i>American Journal of Surgical Pathology</i> , 2014, 38, 354-359.	2.1	18
157	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. <i>Respiratory Medicine</i> , 2018, 142, 66-72.	1.3	18
158	Isolated Pauciimmune Pulmonary Capillaritis Successfully Treated With Rituximab. <i>Chest</i> , 2015, 147, e134-e136.	0.4	17
159	Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial. <i>Open Arthritis Journal</i> , 2011, 4, 1-18.	0.0	17
160	Functional Significance of Asn-linked Glycosylation of Proteinase 3 for Enzymatic Activity, Processing, Targeting, and Recognition by Anti-neutrophil Cytoplasmic Antibodies. <i>Journal of Biochemistry</i> , 2006, 141, 101-112.	0.9	16
161	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	1.1	16
162	Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. <i>Clinical Rheumatology</i> , 2020, 39, 1581-1590.	1.0	16

#	ARTICLE	IF	CITATIONS
163	The Growing Complexity of the Pathology Associated With Cocaine Use. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 167-168.	0.5	15
164	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	1.4	15
165	Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. <i>American Journal of Rhinology & Allergy</i> , 2003, 17, 33-43.	2.3	14
166	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.4	14
167	Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1083-1087.	0.4	13
168	Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis. <i>Respirology Case Reports</i> , 2022, 10, e0894.	0.3	13
169	Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 741-754.	0.8	12
170	Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Clinical and Experimental Immunology</i> , 2017, 188, 174-181.	1.1	12
171	Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw384.	0.4	12
172	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 2077-2086.	2.9	12
173	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020, 59, 519-530.	1.6	12
174	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	2.2	12
175	Plasma exchange for the management of ANCA-associated vasculitis: the con position. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 231-236.	0.4	12
176	A 70-Year-Old Man With Pulmonary Infiltrates and a Positive Antineutrophil Cytoplasmic Autoantibody Test Result. <i>Chest</i> , 2005, 127, 1045-1050.	0.4	11
177	Accuracy of the ICD-9 Code for Identification of Patients with Wegener's Granulomatosis: Table 1. <i>Journal of Rheumatology</i> , 2010, 37, 474-474.	1.0	11
178	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	1.5	11
179	Controversies in ANCA testing. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S7-S11.	0.6	11
180	Echocardiographic features of atrial myocarditis with giant cells: A case report. <i>Journal of the American Society of Echocardiography</i> , 2004, 17, 1073-1076.	1.2	10

#	ARTICLE	IF	CITATIONS
181	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 816-816.	2.5	9
182	TNF-Î± Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 501-508.	2.1	9
183	ANCA subsets: influence on disease phenotype.. Cleveland Clinic Journal of Medicine, 2002, 69, SII56-SII56.	0.6	9
184	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 58-74.	1.2	8
185	Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?. Current Opinion in Rheumatology, 2015, 27, 231-240.	2.0	8
186	Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. International Forum of Allergy and Rhinology, 2020, 10, 217-222.	1.5	8
187	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Chest, 2021, 160, 572-581.	0.4	8
188	Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. Journal of Immunological Methods, 1996, 191, 55-63.	0.6	7
189	Will LAMP enlighten us about ANCA-associated vasculitis?. Nature Reviews Nephrology, 2012, 8, 318-320.	4.1	7
190	Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors. Frontiers in Immunology, 2019, 10, 2467.	2.2	7
191	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. American Journal of Pathology, 2020, 190, 1438-1448.	1.9	7
192	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	2.3	7
193	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 40-44.	0.4	7
194	Epitope-specific anti-neutrophil cytoplasmic antibodies: Do they matter? Can they be detected?. Apmis, 2009, 117, 63-66.	0.9	6
195	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	0.6	6
196	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. Journal of Autoimmunity, 2015, 59, 43-52.	3.0	6
197	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	1.1	6
198	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	1.0	6

#	ARTICLE	IF	CITATIONS
199	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020, 5, .	2.3	6
200	Biologic agents in the treatment of granulomatosis with polyangiitis. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S50-S53.	0.6	6
201	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCAâ€Associated</scp> Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	0.9	6
202	S1. Rituximab for ANCA-associated vasculitis: The experience in the United States. <i>Presse Medicale</i> , 2013, 42, 530-532.	0.8	5
203	Refining phenotypes in ANCA-associated vasculitis. <i>Nature Reviews Nephrology</i> , 2013, 9, 6-8.	4.1	5
204	Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 193-206.	0.6	5
205	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2022, 61, 423-437.	1.6	5
206	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1223-1224.	3.0	5
207	Reply: Further Progress in Understanding Fibrosing Mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 768-768.	2.5	3
208	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibodyâ€associated Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 1243-1243.	1.0	3
209	Interstitial Lung Disease and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Chest</i> , 2021, 159, 2141-2142.	0.4	3
210	Granulomatosis with Polyangiitis (Wegener's). , 0, , 238-251.		3
211	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.4	3
212	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.4	3
213	Acquired cyclic neutropenia associated with cocaineâ€induced antiâ€neutrophil cytoplasmic antibodies binding to human neutrophil elastase. <i>American Journal of Hematology</i> , 2018, 93, E227-E229.	2.0	2
214	Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 64-72.	0.5	2
215	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	0.9	2
216	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2

#	ARTICLE	IF	CITATIONS
217	A Rare Cause Hemoptysis Illustrating the Role of Single Ventricle Physiology in Bronchial Circulatio. Chest, 2011, 140, 83A.	0.4	1
218	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 1081-1082.	0.4	1
219	PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS. Chest, 2018, 154, 1019A-1020A.	0.4	1
220	Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome. Respiratory Medicine Case Reports, 2021, 33, 101432.	0.2	1
221	Pulmonary Vasculitis. , 2012, , 365-386.		1
222	Clinical role of C-ANCA testing. Clinical Immunology Newsletter, 1990, 10, 171-174.	0.1	0
223	Wegener's Granulomatosis and Pulmonary Vasculitis. Clinical Pulmonary Medicine, 1995, 2, 267-275.	0.3	0
224	Tumor necrosis factor γ blockade as therapy for sarcoidosis: Comment on the article by Ulbricht et al. Arthritis and Rheumatism, 2004, 50, 2717-2718.	6.7	0
225	Subtle modifications of a PR3-ANCA ELISA affect assay performance. Clinical Immunology, 2006, 118, 124-125.	1.4	0
226	A REVIEW OF NECROTIZING GRANULOMAS. Chest, 2007, 132, 639A.	0.4	0
227	55-Year-Old Man With Purpura and Foot Pain. Mayo Clinic Proceedings, 2008, 83, 93-96.	1.4	0
228	Response to Rituximab in membranous nephropathy. Kidney International, 2008, 74, 392.	2.6	0
229	Pulmonary Vasculitis and Hemorrhage. , 2012, , 722-730.		0
230	Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality. International Journal of Clinical Rheumatology, 2013, 8, 383-397.	0.3	0
231	Reply. Arthritis and Rheumatology, 2016, 68, 2828-2829.	2.9	0
232	Advances in Management of Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis. Chest, 2016, 150, 536A.	0.4	0
233	Reply. Arthritis and Rheumatology, 2017, 69, 1507-1508.	2.9	0
234	THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
235	053.â€¦CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
236	THU0309â€¦NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0
237	SAT0012â€¦DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
238	SAT0236â€¦RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0
239	Remission maintenance in ANCA-associated vasculitis: does one size fit all?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1273-1286.	1.3	0
240	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , 2020, 59, 1187-1187.	0.9	0
241	The Survival of Patients With Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. <i>Journal of Rheumatology</i> , 2021, 48, 314-317.	1.0	0
242	Vasculitis and Alveolar Hemorrhage. , 2022, , 341-357.		0
243	ANCA-Associated Vasculitis. , 2009, , 245-267.		0
244	Pathogenesis and Management of ANCA-Associated Vasculitis. , 2014, , 137-151.		0
245	Pulmonary Manifestations of Vasculitis. , 2014, , 123-137.		0